• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now

    2/19/25 6:00:00 AM ET
    $AEMD
    $ASPI
    $BDRX
    $BENF
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials
    Get the next $AEMD alert in real time by email

    MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    For updates, follow us on Twitter

    Day 2 - Today

    February 19, 2025

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Light.AI, Inc. (CBOE CA: ALGO) (FSE: 0HC)

    Keynote speaker: Hugh Cleland, Director

    9:40 – 10:10

    Biodexa Pharmaceuticals PLC (NASDAQ:BDRX)

    Keynote speaker: Stephen Anthony Stamp, CEO, CFO & Director

    10:15 – 10:45

    HydroGraph Clean Power Inc. (OTCQB:HGRAF) (CSE:HG)

    Keynote speaker: Kjirstin Breure, President and CEO

    10:50 – 11:20

    22nd Century Group, Inc. (NASDAQ:XXII)

    Keynote speaker: Lawrence D. Firestone, Chairman & CEO

    11:25 – 11:55

    Aethlon Medical, Inc. (NASDAQ:AEMD)

    Keynote speakers: Jim Frakes, Acting CEO and CFO & Steven LaRosa, Chief Medical Officer

    12:00 – 12:30

    Gossamer Bio, Inc. (NASDAQ:GOSS)

    Keynote speaker: Bryan Giraudo, CFO & COO

    12:35 – 1:05

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: Dr. David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

    1:10 - 1:40

    ANGLE, plc. (OTCQX:ANPCY) (AIM: AGL)

    Keynote speakers: Andrew David William Newland, Founder, CEO & Executive Director

    1:45 - 2:15

    Touchstone Explorations, Inc. (OTC:PBEGF) (TSX:TXP) 

    Keynote speaker: Paul Raymond Baay President, CEO

    2:20 – 2:50

    Mesoblast, Ltd. (NASDAQ:MESO)

    Keynote speakers: Dr. Silviu Itescu, Founder, CEO

    2:55 – 3:05

    GeoVax Labs, Inc. (NASDAQ:GOVX)

    Keynote speakers: David Dodd, Chairman, President / CEO

    3:10 - 3:20

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    3:25 - 3:35

    U Power Limited (NASDAQ:UCAR) 

    Keynote speaker: Paul Li, UCAR European Representative

    3:40 – 3:50

    Eloro Resources, Ltd. (OTCQX:ELRRF) (TSX:ELO)

    Keynote speakers: Thomas Larsen, CEO & Chairman, & Dr. William N. Pearson, Executive Vice President of Exploration

    3:55 – 4:05

    The Birch Co. (OTC:ATWT)

    Keynote speaker: Angus Martin, President & CEO

    4:10 – 4:40

    Sigyn Therapeutics, Inc. (OTCQB:SIGY)

    Keynote speaker: James Allen Joyce, CEO

    _______________________________________________________________

    Day 1

    February 18, 2025

    Companies presented yesterday:

    Replay Day 1 here:

    https://emerginggrowth.com/emerging-growth-conference-79/

    B.O.S. Better Online Solutions, Ltd. (NASDAQ:BOSC)

    Keynote speaker: Eyal Cohen, President & CEO

    Brenmiller Energy, Ltd. (NASDAQ:BNRG)

    Keynote speaker: Nir Brenmiller, COO

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    U.S. Energy Corporation (NASDAQ:USEG)

    Keynote speaker: Ryan Smith, President, CEO & Director

    Empire Energy (ASX: EEG)

    Keynote speaker: Alex Underwood, CEO & Managing Director

    Nova Minerals Limited (NASDAQ:NVA) (ASX: NVA) 

    Keynote speaker: Christopher Gerteisen – CEO & Executive Director

    Highland Copper Company Inc. (OTCQB:HDRSF) (TSXV:HI)

    Keynote speaker: Barry O'Shea, CEO

    Collective Mining, Ltd. (NYSE:CNL) (TSX:CNL)

    Keynote speaker: Ari Sussman, Executive Chairman

    Ideal Power, Inc. (NASDAQ:IPWR)

    Keynote speakers: Dan Brdar, President / CEO, and Tim Burns CFO

    West Red Lake Gold Mines Ltd. (OTCQB:WRLGF) (TSXV:WRLG)

    Keynote Speaker: Gwen Preston, Vice President, Communications

    Beneficient (NASDAQ:BENF)

    Keynote speaker: Brad K. Heppner, CEO

    Jaguar Health, Inc. (NASDAQ:JAGX)

    Keynote speaker: Lisa A. Conte, Founder, CEO, President & Director

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, & Harry M. Lander, Ph.D. Senior Scientific Consultant

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    [email protected]

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: [email protected]



    Primary Logo

    Get the next $AEMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ASPI
    $BDRX
    $BENF

    CompanyDatePrice TargetRatingAnalyst
    Gossamer Bio Inc.
    $GOSS
    9/10/2025$9.00Neutral → Buy
    UBS
    Mesoblast Limited
    $MESO
    7/18/2025Buy → Hold
    Jefferies
    Gossamer Bio Inc.
    $GOSS
    7/14/2025$11.00Sector Outperform
    Scotiabank
    Aethlon Medical Inc.
    $AEMD
    7/7/2025$1.50Neutral
    H.C. Wainwright
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$18.00 → $14.00Buy
    D. Boral Capital
    GeoVax Labs Inc.
    $GOVX
    4/15/2025$15.00 → $8.50Buy
    Alliance Global Partners
    Mesoblast Limited
    $MESO
    12/23/2024Buy → Hold
    Jefferies
    Longeveron Inc.
    $LGVN
    12/6/2024$10.00Buy
    ROTH MKM
    More analyst ratings

    $AEMD
    $ASPI
    $BDRX
    $BENF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Somo David M was granted 247,438 shares (SEC Form 4)

    4 - Ideal Power Inc. (0001507957) (Issuer)

    11/5/25 4:06:58 PM ET
    $IPWR
    Semiconductors
    Technology

    SEC Form 3 filed by new insider Somo David M

    3 - Ideal Power Inc. (0001507957) (Issuer)

    11/5/25 4:06:21 PM ET
    $IPWR
    Semiconductors
    Technology

    Member of 10% owner group Weinzierl John A acquired 796,761 shares and disposed of 1,400,000 shares (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    10/30/25 6:16:11 PM ET
    $USEG
    Oil & Gas Production
    Energy

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Announces Quantum Leap Energy's Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

    WASHINGTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) today announced that its wholly-owned subsidiary, Quantum Leap Energy LLC ("QLE"), has confidentially submitted a draft registration statement on Form S-1 to the Securities and Exchange Commission (the "SEC") relating to the proposed initial public offering of QLE's Class A common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed initial public offering remains subject to the completion of the SEC review process as well as market and other conditions. This press release is being issued pursuant to, and in accordance with, Rule 135 p

    11/12/25 5:17:56 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Longeveron Granted U.S. Patent for Method of Treating Aging-related Frailty in Patients with Inflammaging Using its Proprietary Stem Cell Therapy

    The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammagingNo approved treatments for aging-related frailty, a syndrome affecting older individuals that impairs human Healthspan, and is characterized by weakness, low physical activity, slowed motor performance, exhaustion, and unintentional weight lossLaromestrocel, a mesenchymal stem cell therapy, has delivered positive initial results across two clinical trials in aging-related frailty MIAMI, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing ce

    11/12/25 9:05:00 AM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Gossamer Bio upgraded by UBS with a new price target

    UBS upgraded Gossamer Bio from Neutral to Buy and set a new price target of $9.00

    9/10/25 7:56:26 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mesoblast downgraded by Jefferies

    Jefferies downgraded Mesoblast from Buy to Hold

    7/18/25 8:10:38 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Scotiabank initiated coverage on Gossamer Bio with a new price target

    Scotiabank initiated coverage of Gossamer Bio with a rating of Sector Outperform and set a new price target of $11.00

    7/14/25 8:51:47 AM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    SEC Filings

    View All

    SEC Form 10-Q filed by Aethlon Medical Inc.

    10-Q - AETHLON MEDICAL INC (0000882291) (Filer)

    11/12/25 5:10:42 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    11/12/25 4:31:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Aethlon Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    11/12/25 4:16:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO Smith Ryan Lewis bought $4,560 worth of shares (4,000 units at $1.14), increasing direct ownership by 0.34% to 1,183,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    9/15/25 7:00:12 AM ET
    $USEG
    Oil & Gas Production
    Energy

    Director Milligan Sandra bought $50,016 worth of shares (26,050 units at $1.92), increasing direct ownership by 81% to 58,050 units (SEC Form 4)

    4 - Gossamer Bio, Inc. (0001728117) (Issuer)

    8/20/25 4:04:35 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Smith Ryan Lewis bought $2,340 worth of shares (2,000 units at $1.17), increasing direct ownership by 0.17% to 1,179,039 units (SEC Form 4)

    4 - US ENERGY CORP (0000101594) (Issuer)

    8/14/25 7:00:13 AM ET
    $USEG
    Oil & Gas Production
    Energy

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Gossamer Bio Inc. on Jun 21

    Gossamer Bio Inc. recently witnessed an insider purchase by COO/CFO Bryan Giraudo, who acquired $59,110 worth of shares consisting of 100,000 units at $0.59 per share. Insider purchases like this can provide valuable insights for investors, indicating confidence from individuals within the company about its future prospects. Examining previous insider transactions, on 2024-03-19, insiders Peterson Caryn and Aranda Richard each sold $5,343 worth of shares at $1.33, leading to a decrease in their direct ownership percentages. Similarly, on 2024-03-28, Hasnain Faheem, Giraudo Bryan, and Christian Waage sold shares worth $26,773, $7,431, and $7,430, respectively, impacting their direct ownershi

    6/21/24 3:17:31 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Financials

    Live finance-specific insights

    View All

    Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update

    Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m. ET SAN DIEGO, Nov. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Compliance matters resolved, Aethlon remains in good standing with Nasdaq.Clinical Progress: Recruitment underway for Cohort 2 of the Australian oncology trial under amended protoc

    11/12/25 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025

    SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal second quarter ended September 30, 2025, at 4:15 p.m. ET on Wednesday, November 12, 2025. Management will host a conference call on Wednesday, November 12, 2025, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10204579/

    11/7/25 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

    - Topline Results from PROSERA Phase 3 Expected in February 2026 - - First Site Activated for Registrational Phase 3 SERANATA Study in PH-ILD - - Cash, cash equivalents and marketable securities totaled $180 million as of September 30 - Gossamer Bio, Inc. (NASDAQ:GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter ended September 30, 2025, and provided a business update. Gossamer Bio and the Chiesi Group are jointly developing

    11/5/25 4:01:00 PM ET
    $GOSS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Mesoblast Limited

    SC 13G/A - MESOBLAST LTD (0001345099) (Subject)

    12/16/24 12:08:07 PM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Brenmiller Energy Ltd

    SC 13D/A - Brenmiller Energy Ltd. (0001901215) (Subject)

    12/5/24 11:18:20 AM ET
    $BNRG
    Building Products
    Industrials

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $AEMD
    $ASPI
    $BDRX
    $BENF
    Leadership Updates

    Live Leadership Updates

    View All

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Interim results for the six months ended June 30, 2025

    September 12, 2025 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces its unaudited interim results for the six months ended June 30, 2025 which will also be made available on the Company's website at www.biodexapharma.com. OPERATIONAL HIGHLIGHTS The Company announced the following in the six months ended June 30, 2025: Allowance by the US Patent and Trademark Office of patent application No. 17/391-495 "Oral Rapamycin Nanopart

    9/12/25 8:30:00 AM ET
    $BDRX
    Biotechnology: Pharmaceutical Preparations
    Health Care